🟢 Chemours is trading 6% up in after-hours trading as 2026 EBITDA outlook supports gains

Chemours is trading 5.70% higher at $13.90 after its November 2, 2026, after-hours earnings release, with the 2026 outlook potentially supporting the positive reaction.

• Third-quarter revenue of $1.54 billion and adjusted EBITDA of $200 million increased year over year.
• Adjusted EPS was $0.21, below the $0.27 consensus.
• The company projected full-year adjusted EBITDA of $775 million to $800 million and net leverage below 4.2x, despite weaker TSS results.